Ontology highlight
ABSTRACT: Purpose
Genomic methods can identify homologous recombination deficiency (HRD). Rigorous evaluation of their outcome association to DNA damage response-targeted therapies like platinum in pancreatic ductal adenocarcinoma (PDAC) is essential in maximizing therapeutic outcome.Experimental design
We evaluated progression-free survival (PFS) and overall survival (OS) of patients with advanced-stage PDAC, who had both germline- and somatic-targeted gene sequencing. Homologous recombination gene mutations (HRm) were evaluated: BRCA1, BRCA2, PALB2, ATM, BAP1, BARD1, BLM, BRIP1, CHEK2, FAM175A, FANCA, FANCC, NBN, RAD50, RAD51, RAD51C, and RTEL1 HRm status was grouped as: (i) germline versus somatic; (ii) core (BRCAs and PALB2) versus non-core (other HRm); and (iii) monoallelic versus biallelic. Genomic instability was compared using large-scale state transition, signature 3, and tumor mutation burden.Results
Among 262 patients, 50 (19%) had HRD (15% germline and 4% somatic). Both groups were analyzed together due to lack of difference in their genomic instability and outcome. Median [95% confidence interval (CI)] follow-up was 21.9 (1.4-57.0) months. Median OS and PFS were 15.5 (14.6-19) and 7 (6.1-8.1) months, respectively. Patients with HRD had improved PFS compared with no HRD when treated with first-line (1L) platinum [HR, 0.44 (95% CI: 0.29-0.67); P < 0.01], but not with 1L-non-platinum. Multivariate analysis showed HRD patients had improved OS regardless of their first-line treatment, but most had platinum exposure during their course. Biallelic HRm (11%) and core HRm (12%) had higher genomic instability, which translated to improved PFS on first-line platinum (1L-platinum) versus 1L-non-platinum.Conclusions
Pathogenic HRm identifies HRD in patients with PDAC with the best outcome when treated with 1L-platinum. Biallelic HRm and core HRm further enriched benefit from 1L-platinum from HRD.
SUBMITTER: Park W
PROVIDER: S-EPMC7380542 | biostudies-literature | 2020 Jul
REPOSITORIES: biostudies-literature
Park Wungki W Chen Jiapeng J Chou Joanne F JF Varghese Anna M AM Yu Kenneth H KH Wong Winston W Capanu Marinela M Balachandran Vinod V McIntyre Caitlin A CA El Dika Imane I Khalil Danny N DN Harding James J JJ Ghalehsari Nima N McKinnell Zoe Z Chalasani Sree B SB Makarov Vladimir V Selenica Pier P Pei Xin X Lecomte Nicolas N Kelsen David P DP Abou-Alfa Ghassan K GK Robson Mark E ME Zhang Liying L Berger Michael F MF Schultz Nikolaus N Chan Timothy A TA Powell Simon N SN Reis-Filho Jorge S JS Iacobuzio-Donahue Christine A CA Riaz Nadeem N O'Reilly Eileen M EM
Clinical cancer research : an official journal of the American Association for Cancer Research 20200522 13
<h4>Purpose</h4>Genomic methods can identify homologous recombination deficiency (HRD). Rigorous evaluation of their outcome association to DNA damage response-targeted therapies like platinum in pancreatic ductal adenocarcinoma (PDAC) is essential in maximizing therapeutic outcome.<h4>Experimental design</h4>We evaluated progression-free survival (PFS) and overall survival (OS) of patients with advanced-stage PDAC, who had both germline- and somatic-targeted gene sequencing. Homologous recombin ...[more]